Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework

Biophysical Journal

Volumn 99, Issue 10, 2010, Pages 3445-3453

  Bellows, M L ^a   Taylor, M S ^b   Cole, P A ^b   Shen, L ^b   Siliciano, R F ^b,c   FungH K , ^a   Floudas, C A ^a  

^a Princeton University   (United States)

^b Department of Pharmacology and Molecular Sciences ^*  (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78649244595     PISSN: 00063495     EISSN: 15420086     Source Type: Journal    
DOI: 10.1016/j.bpj.2010.09.050     Document Type: Article

References (73)

1. UNAIDS. 2008. 2008 Report on the Global AIDS Epidemic. XVII International AIDS Conference, International AIDS Society, Geneva, Switzerland.
2. Thayer, A. M. 2008. Resetting priorities. Chem. Eng. News. 86:17-28.
3. Thayer, A. M. 2008. New antiretrovirals. Chem. Eng. News. 86:29-36.
4. Chan, D. C., and P. S. Kim. 1998. HIV entry and its inhibition. Cell. 93:681-684.
5. Liu, S.W., S. G.Wu, and S. B. Jiang. 2007. HIVentry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr. Pharm. Des. 13:143-162.
6. Qi, Z., W. G. Shi, ., S. Jiang. 2008. Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors. J. Biol. Chem. 283:30376-30384.
7. Shen, L., S. Peterson, ., R. F. Siliciano. 2008. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat. Med. 14:762-766.
8. Dorr, P., M. Westby, ., M. Perros. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:4721-4732.
9. Welch, B. D., A. P. VanDemark,., M. S. Kay. 2007. Potent D-peptide inhibitors of HIV-1 entry. Proc. Natl. Acad. Sci. USA. 104:16828-16833.
10. Sia, S. K., P. A. Carr, ., P. S. Kim. 2002. Short constrained peptides that inhibit HIV-1 entry. Proc. Natl. Acad. Sci. USA. 99:14664-14669.
11. Izumi, K., E. Kodama, ., M. Matsuoka. 2009. Design of peptidebased inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. J. Biol. Chem. 284:4914-4920.
12. Naito, T., K. Izumi,., M. Matsuoka. 2009. SC29EK, a peptide fusion inhibitor with enhanced a-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to Enfuvirtide. Antimicrob. Agents Chemother. 53:1013-1018.
13. Nishikawa, H., S. Nakamura,., M. Matsuoka. 2009. Electrostatically constrained α-helical peptide inhibits replication of HIV-1 resistant to Enfuvirtide. Int. J. Biochem. Cell Biol. 41:891-899.
14. Dwyer, J. J., K. L. Wilson, ., M. K. Delmedico. 2007. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against Enfuvirtide-resistant virus. Proc. Natl. Acad. Sci. USA. 104:12772-12777.
15. He, Y., Y. Xiao, ., L. Zhang. 2008. Design and evaluation of Sifuvirtide, a novel HIV-1 fusion inhibitor. J. Biol. Chem. 283:11126-11134.
16. Balogh, E., D. Wu, ., M. Gochin. 2009. NMR second site screening for structure determination of ligands bound in the hydrophobic pocket of HIV-1 gp41. J. Am. Chem. Soc. 131:2821-2823.
17. Lu, R. J., J. A. Tucker, ., C. Sexton. 2007. Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the α-ketoamide group. J. Med. Chem. 50:6535-6544.
18. Li, G., K. M. Haney,., Y. Zhang. 2009. Comparative docking study of anibamine as the first natural product CCR5 antagonist in CCR5 homology models. J. Chem. Inf. Model. 49:120-132.
19. Madani, N., A. Schön, ., J. Sodroski. 2008. Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure. 16:1689-1701.
20. Liu, K., H. Lu,., L. Xie. 2008. Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41. J. Med. Chem. 51:7843-7854.
21. Maheshwari, R., E. A. Levenson, and K. L. Kiick. 2010. Manipulation of electrostatic and saccharide linker interactions in the design of efficient glycopolypeptide-based cholera toxin inhibitors. Macromol. Biosci. 10:68-81.
22. Ingallinella, P., E. Bianchi,., A. Pessi. 2009. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc. Natl. Acad. Sci. USA. 106:5801-5806.
23. Berchanski, A., and A. Lapidot. 2009. Computer-based design of novel HIV-1 entry inhibitors: neomycin conjugated to arginine peptides at two specific sites. J. Mol. Model. 15:281-294.
24. Imai, M., L. Baranyi,., H. Okada. 2007. Inhibition of HIV-1 infection by synthetic peptides derived CCR5 fragments. Biochem. Biophys. Res. Commun. 353:851-856.
25. Fung, H. K., W. J. Welsh, and C. A. Floudas. 2008. Computational de novo peptide and protein design: rigid templates versus flexible templates. Ind. Eng. Chem. Res. 47:993-1001.
26. Floudas, C. A., H. K. Fung,., R. Rajgaria. 2006. Advances in protein structure prediction and de novo protein design: a review. Chem. Eng. Sci. 61:966-988.
27. Kortemme, T., and D. Baker. 2004. Computational design of proteinprotein interactions. Curr. Opin. Chem. Biol. 8:91-97.
28. Kuhlman, B., and D. Baker. 2004. Exploring folding free energy landscapes using computational protein design. Curr. Opin. Struct. Biol. 14:89-95.
29. Desmet, J., M. D. Maeyer, ., I. Lasters. 1992. The dead-end elimination theorem and its use in side-chain positioning. Nature. 356: 539-542.
30. Pierce, N., J. Spriet, ., S. Mayo. 2000. Conformational splitting: a more powerful criterion for dead-end elimination. J. Comput. Chem. 21:999-1009.
31. Georgiev, I., and B. R. Donald. 2007. Dead-end elimination with backbone flexibility. Bioinformatics. 23:i185-i194.
32. Koehl, P., and M. Delarue. 1994. Application of a self-consistent mean field theory to predict protein side-chains conformation and estimate their conformational entropy. J. Mol. Biol. 239:249-275.
33. Saven, J. G. 2002. Combinatorial protein design. Curr. Opin. Struct. Biol. 12:453-458.
34. Zou, J. M., and J. G. Saven. 2003. Using self-consistent fields to bias Monte Carlo methods with applications to designing and sampling protein sequences. J. Chem. Phys. 118:3843-3854.
35. Koehl, P., and M. Levitt. 1999. De novo protein design. I. In search of stability and specificity. J. Mol. Biol. 293:1161-1181.
36. Koehl, P., and M. Levitt. 1999. De novo protein design. II. Plasticity in sequence space. J. Mol. Biol. 293:1183-1193.
37. Dantas, G., B. Kuhlman, ., D. Baker. 2003. A large scale test of computational protein design: folding and stability of nine completely redesigned globular proteins. J. Mol. Biol. 332:449-460.
38. Su, A., and S. L. Mayo. 1997. Coupling backbone flexibility and amino acid sequence selection in protein design. Protein Sci. 6:1701-1707.
39. Saunders, C. T., and D. Baker. 2005. Recapitulation of protein family divergence using flexible backbone protein design. J. Mol. Biol. 346:631-644.
40. Fung, H. K., M. S. Taylor, and C. A. Floudas. 2007. Novel formulations for the sequence selection problem in de novo protein design with flexible templates. Optimiz. Meth. Softw. 22:51-71.
41. Dong, X.-N., Y. Xiao,., Y. H. Chen. 2001. N- and C-domains of HIV- 1 gp41: mutation, structure and functions. Immunol. Lett. 75:215-220.
42. Eckert, D. M., V. N. Malashkevich,., P. S. Kim. 1999. Inhibiting HIV- 1 entry: discovery of D-peptide inhibitors that target the gp41 coiledcoil pocket. Cell. 99:103-115.
43. Chan, D. C., C. T. Chutkowski, and P. S. Kim. 1998. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. USA. 95:15613-15617.
44. Chan, D. C., D. Fass,., P. S. Kim. 1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 89:263-273.
45. Fung, H. K., C. A. Floudas,., D. Morikis. 2008. Toward full-sequence de novo protein design with flexible templates for human b-defensin-2. Biophys. J. 94:584-599.
46. Rajgaria, R., S. R. McAllister, and C. A. Floudas. 2006. A novel high resolution Ca-Ca distance dependent force field based on a high quality decoy set. Proteins: Struct. Funct. Bioinf. 65:726-741.
47. Rajgaria, R., S. R. McAllister, and C. A. Floudas. 2008. Distance dependent centroid to centroid force fields using high resolution decoys. Proteins. 70:950-970.
48. Loose, C., J. Klepeis, and C. Floudas. 2004. A new pairwise folding potential based on improved decoy generation and side chain packing. Proteins: Struct. Funct. Bioinf. 54:303-314.
49. Klepeis, J. L., C. A. Floudas, ., J. D. Lambris. 2003. Integrated computational and experimental approach for lead optimization and design of compstatin variants with improved activity. J. Am. Chem. Soc. 125:8422-8423.
50. Klepeis, J. L., C. A. Floudas,., J. D. Lambris. 2004. Design of peptide analogs with improved activity using a novel de novo protein design approach. Ind. Eng. Chem. Res. 43:3817-3826.
51. Klepeis, J. L., and C. A. Floudas. 2003. ASTRO-FOLD: A combinatorial and global optimization framework for ab initio prediction of threedimensional structures of proteins from the amino acid sequence. Biophys. J. 85:2119-2146.
52. Klepeis, J. L., C. A. Floudas, D. Morikis, and J. D. Lambris. 1999. Predicting peptide structures using NMR data and deterministic global optimization. J. Comput. Chem. 20:1354-1370.
53. Klepeis, J. L., and C. A. Floudas. 1999. Free energy calculations for peptides via deterministic global optimization. J. Chem. Phys. 110: 7491-7512.
54. Floudas, C. A. 2007. Computational methods in protein structure prediction. Biotechnol. and Bioeng. 97:207-213.
55. Güntert, P., C. Mumenthaler, and K. Wüthrich. 1997. Torsion angle dynamics for NMR structure calculation with the new program DYANA. J. Mol. Biol. 273:283-298.
56. Guntert, P. 2004. Automated NMR structure calculation with CYANA. Meth. Mol. Biol. J. Mol. Biol. 278:353-378.
57. Ponder, J. 1998. TINKER, software tools for molecular design. Department of Biochemistry and Molecular Biophysics. Washington University School of Medicine, St. Louis, MO.
58. Cornell, W. D., P. Cieplak, ., P. A. Kollman. 1995. A 2nd generation force-field for the simulation of proteins, nucleic-acids, and organicmolecules. J. Am. Chem. Soc. 117:5179-5197.
59. Bellows, M. L., H. K. Fung, ., D. Morikis. 2010. New compstatin variants through two de novo protein design frameworks. Biophys. J. 98:2337-2346.
60. Lilien, R. H., B. W. Stevens, ., B. R. Donald. 2005. A novel ensemble-based scoring and search algorithm for protein redesign and its application to modify the substrate specificity of the gramicidin synthetase a phenylalanine adenylation enzyme. J. Comput. Biol. 12:740-761.
61. Lee, M. R., D. Baker, and P. A. Kollman. 2001. 2.1 and 1.8Å average C (a) RMSD structure predictions on two small proteins, HP-36 and s15. J. Am. Chem. Soc. 123:1040-1046.
62. Rohl, C. A., and D. Baker. 2002. De novo determination of protein backbone structure from residual dipolar couplings using Rosetta. J. Am. Chem. Soc. 124:2723-2729.
63. Rohl, C. A., C. E. M. Strauss, ., D. Baker. 2004. Protein structure prediction using Rosetta. Methods Enzymol. 383:66-93.
64. DiMaggio, Jr., P. A., S. R. McAllister, ., H. A. Rabitz. 2008. Biclustering via optimal re-ordering of data matrices in systems biology: rigorous methods and comparative studies. BMC Bioinformatics. 9:458.
65. DiMaggio, P. A., S. R. McAllister, ., H. A. Rabitz. 2010. A network flow model for biclustering via optimal re-ordering of data matrices. J. Glob. Optim. 47:343-354.
66. Daily, M. D., D. Masica,., J. J. Gray. 2005. CAPRI rounds 3-5 reveal promising successes and future challenges for RosettaDock. Proteins. 60:181-186.
67. Gray, J. J., S. E. Moughon,., D. Baker. 2003. Protein-protein docking predictions for the CAPRI experiment. Proteins. 52:118-122.
68. Gray, J. J., S. Moughon, ., D. Baker. 2003. Protein-protein docking with simultaneous optimization of rigid-body displacement and sidechain conformations. J. Mol. Biol. 331:281-299.
69. Kuhlman, B., and D. Baker. 2000. Native protein sequences are close to optimal for their structures. Proc. Natl. Acad. Sci. USA. 97:10383-10388.
70. Zhang, H., Y. Zhou, ., R. F. Siliciano. 2004. Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J. Virol. 78:1718-1729.
71. Poveda, E., B. Rodés,., V. Soriano. 2004. Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J. Med. Virol. 74:21-28.
72. Bailey, J. R., K. G. Lassen,., R. F. Siliciano. 2006. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J. Virol. 80:4758-4770.
73. DeLano, W. L. 2002. The PyMOL molecular graphics system. http:// www.pymol.org .